|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-8-27
|
|
pubmed:abstractText |
Retinoblastoma patients with RB1 germline mutations are at risk of developing second malignancies and external beam radiation therapy increases the risk. Carboplatin-containing chemotherapy regimens in conjunction with local therapies have been investigated for intraocular retinoblastoma, but the lack of data regarding the efficacy of single agent intravenous carboplatin prompted this phase II study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1545-5009
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2007 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
643-8
|
|
pubmed:dateRevised |
2009-1-12
|
|
pubmed:meshHeading |
pubmed-meshheading:17301956-Antineoplastic Agents,
pubmed-meshheading:17301956-Carboplatin,
pubmed-meshheading:17301956-Combined Modality Therapy,
pubmed-meshheading:17301956-Disease-Free Survival,
pubmed-meshheading:17301956-Female,
pubmed-meshheading:17301956-Humans,
pubmed-meshheading:17301956-Infant,
pubmed-meshheading:17301956-Infant, Newborn,
pubmed-meshheading:17301956-Male,
pubmed-meshheading:17301956-Neoadjuvant Therapy,
pubmed-meshheading:17301956-Remission Induction,
pubmed-meshheading:17301956-Retinoblastoma,
pubmed-meshheading:17301956-Survival Analysis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A phase II trial of carboplatin for intraocular retinoblastoma.
|
|
pubmed:affiliation |
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. dunkeli@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
